DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
73.52
-1.80 (-2.39%)
At close: Mar 25, 2025, 4:00 PM
73.56
+0.04 (0.05%)
After-hours: Mar 25, 2025, 6:26 PM EST
DexCom Revenue
In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth. DexCom had revenue of $1.11B in the quarter ending December 31, 2024, with 7.64% growth.
Revenue (ttm)
$4.03B
Revenue Growth
+11.34%
P/S Ratio
7.18
Revenue / Employee
$391,553
Employees
10,300
Market Cap
28.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
DXCM News
- 8 hours ago - Dexcom Appoints Jon Coleman as Chief Commercial Officer - Business Wire
- 12 hours ago - Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom - Business Wire
- 6 days ago - Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care - Business Wire
- 11 days ago - History Says Shut Up And Buy: 12 Hyper-Growth Blue Chips To Buy Right Now - Seeking Alpha
- 15 days ago - Dexcom Appoints Renée Galá to Board of Directors - Business Wire
- 18 days ago - Dexcom receives FDA warning letter for two U.S. manufacturing facilities - Reuters
- 18 days ago - DexCom Gets FDA Warning Letter After Inspections of Facilities - WSJ
- 21 days ago - DexCom, Inc. (DXCM) Presents at 46th Annual Raymond James Institutional Investors Brokers Conference (Transcript) - Seeking Alpha